You are here:

Archived: quetiapine fumerate (Seroquel)


Following a full submission

quetiapine (Seroquel) is not recommended for use within NHS Scotland for the treatment of major depressive episodes associated with bipolar disorder.

In monotherapy studies quetiapine was superior to placebo and compared favourably with two active comparators. Efficacy relative to current practice for the management of depression in the framework of bipolar disorder in NHS Scotland involving combination therapy with a mood stabiliser or an atypical antipsychotic plus an antidepressant, was not demonstrated.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: quetiapine fumerate (Seroquel)
SMC Drug ID: 549/09
Manufacturer: AstraZeneca UK Ltd
Indication: Bipolar disorder
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 October 2009

Current Advice

Resubmission 9 May 2011